Loading provider…
Loading provider…
Hematology & Oncology Physician in New York, NY
NPI: 1316926330Primary Practice Location
Manhattan Hematology Oncology Assoc, PC
157 E 32nd St, New York, NY
Primary Employer
Manhattan Hematology Oncology Assoc, PC
mhony.com
HQ Phone
Get MD Alec's Phone NumberMobile
Get MD Alec's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNY State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 542 | 3,105 |
| 2 | 36415Insertion of needle into vein for collection of blood sample | 502 | 3,165 |
| 3 | 85025Complete blood cell count (red cells, white blood cell, platelets), automated test | 502 | 3,163 |
| 4 | 99213Established patient office or other outpatient visit, typically 15 minutes | 117 | 668 |
| 5 | 99215Established patient office or other outpatient, visit typically 40 minutes | 114 | 115 |
Chronic thalidomide and chemoembolization for hepatocellular carcinoma.
Authors: Joseph Sparano
Publication Date: 2014-11-02
Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry.
Authors: Parvez Mantry, Brendan Mcguire, Allen Cohn, Pierre Gholam
Publication Date: 2016-03-16
Use of Transarterial Chemoembolization (TACE) and Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: US Regional Analysis of the GIDEON Registry.
Authors: Parvez Mantry, Joanne Imperial, Jean-Francois Geschwind, Allen Cohn, Pierre Gholam
Publication Date: 2016-03-19
Lead Sponsor: Aptose Biosciences Inc.
Intervention / Treatment: DRUG: CG-806
Lead Sponsor: Oncternal Therapeutics, Inc
Collaborators: University of California, San Diego, California Institute for Regenerative Medicine (CIRM), Pharmacyclics LLC.
Intervention / Treatment: DRUG: Ibrutinib alone, DRUG: Cirmtuzumab (2-16 kg/mg) plus Ibrutinib, DRUG: Cirmtuzumab (300mg) plus Ibrutinib, DRUG: Cirmtuzumab (600 mg) plus ibrutinib, DRUG: Cirmtuzumab (RDR) plus ibrutinib, DRUG: Cirmtuzumab plus ibrutinib